You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for Patent: 7,732,615

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,732,615 protect, and when does it expire?

Patent 7,732,615 protects NUPLAZID and is included in two NDAs.

This patent has fifty patent family members in eighteen countries.

Summary for Patent: 7,732,615

Title:	N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phe- nylmethyl)carbamide and its tartrate salt and crystalline forms
Abstract:	Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2 -methylpropyloxy)-phenylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
Inventor(s):	Thygesen; Mikkel Boas (Copenhagen East, DK), Schlienger; Nathalie (Frederiksberg, DK), Tolf; Bo-Ragnar (Malmo, SE), Andersson; Carl-Magnus A. (Hjarup, SE), Blatter; Fritz (Reinach, CH), Berghausen; Jorg (Lorrach, DE)
Assignee:	ACADIA Pharmaceuticals Inc. (San Diego, CA)
Application Number:	11/235,558
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,732,615
Patent Claim Types: see list of patent claims	Compound; Process; Composition;

Drugs Protected by US Patent 7,732,615

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	CAPSULE;ORAL	210793-001	Jun 28, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-002	Jun 28, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Acadia Pharms Inc	NUPLAZID	pimavanserin tartrate	TABLET;ORAL	207318-001	Apr 29, 2016		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,732,615

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005289444	⤷ Sign Up
Australia	2005289635	⤷ Sign Up
Australia	2008254238	⤷ Sign Up
Brazil	PI0516063	⤷ Sign Up
Canada	2580129	⤷ Sign Up
Canada	2580136	⤷ Sign Up
Canada	2652300	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.